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Abstract
The mucopolysaccharidoses (MPS) comprise a heterogeneous family of rare, genetic lysosomal storage disorders
that result in severe morbidity and reduced life expectancy. Emerging treatments for several of these disorders have
triggered the search for clinically relevant biomarkers and clinical markers associated with treatment efficacy in
populations and individuals. However, biomedical measures do not tell the whole story when characterizing a
complex chronic disorder such as MPS. Health-related quality of life (HRQoL) tools that utilize patient reported
outcomes to address patient parameters such as symptoms (pain, fatigue, psychological health), functioning
(activity and limitations), or quality of life, have been used to supplement traditional biomedical endpoints. Many of
these HRQoL tools have demonstrated that quality of life is negatively impacted in patients with MPS. There is both
the opportunity and need to formally standardize and validate HRQoL tools for the different MPS disorders.
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Background
The mucopolysaccharidoses (MPS) are a group of lyso-
somal storage disorders associated with accumulation of
glycosaminoglycans (GAGs) in tissues and organs due to
enzyme deficiencies required for degradation of cellular
GAGs (Additional file 1). Shared clinical features of the
MPS disorders include skeletal deformities such as ky-
phosis, scoliosis, pectus carinatum, valgus deformities of
the knees, and carpal tunnel syndrome, joint abnormalities,
spinal cord compression, reduced growth, coarse facial fea-
tures, vision and hearing damage, and cardiorespiratory
manifestations [1, 2]. Intellectual and neurological impair-
ment occurs in some MPS subtypes (I, II, III, and VII) due
to GAG accumulation in the brain [1, 2]. MPS patients gen-
erally appear healthy at birth with clinical manifestations
gradually worsening with age. There is a wide variety of
clinical presentations and progression rates among the dif-
ferent MPS subtypes, and within the diseases themselves.
Many of these disorders lead to severe morbidity and
premature death [3].
Therapies including enzyme replacement therapy (ERT)
and hematopoietic stem cell transplantation (HSCT) have
altered the course of morbidity and mortality for some of
the MPS disorders [4, 5]. Biochemical and clinical mea-
sures assessing clinical benefit for regulatory purposes
have been well characterized for several of the MPS disor-
ders and include urine GAG metabolites, 6-min walk test
and pulmonary function tests. What these biomedical
endpoints mean in daily life to patients and their care-
givers is less well understood; and payers are increasingly
asking for evidence that these treatments are having an ef-
fect that is “meaningful” to both patients and families.
The term “quality of life” is an expansive multi-
dimensional concept that typically includes subjective
assessments of both positive and negative aspects of life
[6]. While health is an important facet of overall quality
of life, it is not the only one. Other aspects, including
occupation, environs, school, ethos, beliefs, and spiritu-
ality are important domains of quality of life and add to
the inherent difficulty of its measurement. The concept
of “health-related quality of life (HRQoL),” specifically
comprises those areas of quality of life that can clearly
be shown to affect health – physical, mental, emotional,
and social functioning. In fact, the U.S. Centers for Dis-
ease Control has defined HRQoL as “an individual’s or
group’s perceived physical and mental health over time”
[7]. It should be noted that HRQoL is usually measured
through self-assessment; however, if the patient is too ill
or too young, a caregiver/parent assessment can serve as
proxy.
In many disease states, HRQoL tools that attempt to
measure patient or caregiver outcomes, are used to sup-
plement traditional measures of morbidity, mortality and
the effects of treatment. The purpose of this review is to
survey the HRQoL tools that have been used to study
MPS disorders, and to examine the impact of treatments
on patient reported outcomes (PROs).
Methodology
Relevant literature was obtained from clinical trial publica-
tions and PubMed searches for MeSH terms “(quality of
life[MeSH Terms]) AND mucopolysaccharidoses[MeSH
Terms]” (30 articles) and free text “(mucopolysaccharidosis)
AND [(quality of life) or (pain) or (fatigue)]” (151 articles).
Additional publications were identified from reference lists
within the most relevant MPS-related papers focusing on
PROs, fatigue, pain, and HRQoL. The literature search was
completed in June 2015.
How does MPS affect HRQoL?
The multi-organ clinical manifestations of MPS can lead
to poor endurance and mobility, often associated with
pain, restricted range of motion (ROM), low energy levels,
and fatigue which negatively affect HRQoL and activities
of daily living (ADL) (Fig. 1). MPS patients may experience
increased physical and emotional dependence on family
and friends, reduced participation in school, work and so-
cial life, low self-esteem, and psychological, behavioral and
mental health conditions such as anxiety and depression
(Fig. 1) [8]. Impaired vision and hearing and frequent
surgeries may further reduce physical activity, while
negatively affecting interpersonal functioning, social life,
educational engagement, employment, and the ability to
live independently [9–12] (Fig. 1).
Impaired mobility is prevalent in MPS patients, with
many individuals requiring walking aids or a wheelchair
[11, 13–15] (Fig. 2). Mobility problems may be due to
skeletal and joint abnormalities, spinal cord compression,
pain in the lower extremities, and reduced energy levels
caused by cardiorespiratory issues [2]. Joint abnormalities
can result in poor shoulder ROM, wrist weakness, stiffness
or changes in mobility which in turn affect simple ADL
tasks such as dressing, washing and eating [16]. Pain may
arise from joint defects, infections including otitis media,
neurological involvement and neuropathic signals arising
in the brain, increased intracranial pressure, spinal cord
compression, or carpal tunnel syndrome [13, 15, 17]. Fa-
tigue, the result of impaired cardiopulmonary function,
can produce stress, anger, frustration, and potentially
depression [18].
Patient Reported Outcome (PRO) measures in MPS
PRO measures are collected by standardized question-
naires designed to measure explicit concepts such as
symptoms (pain, fatigue, psychological health), functioning
(activity limitations), HRQoL, or quality of life (QoL) [19].
Thousands of PRO instruments have been described in-
cluding both generic and disease-specific questionnaires
Hendriksz et al. Orphanet Journal of Rare Diseases  (2016) 11:119 Page 2 of 15
[20, 21]. The advantage of generic questionnaires lies in
their broad applicability across different disease types, se-
verities and medical interventions, and among diverse
demographic and cultural groups, allowing comparison
across studies and diseases [22]. Disease-specific question-
naires are intended for a particular patient population with
questions designed to be relevant, meaningful and accept-
able for that affected population, and may be used to meas-
ure the efficacy of interventions and treatments. PROs used
in clinical trials with MPS patients are summarized in
Table 1 and in Additional file 2, including information re-
garding age ranges, outcomes, and type of respondent.
Fig. 1 Important factors affecting HRQoL in patients with MPS. Some of the manifestations may also have a direct impact on ADL, participation
in school/employment or social life (due to e.g. surgery, cognitive impairment)
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Fig. 2 Mobility impairment in the International Morquio A registry (including 326 patients with MPS IVA) [14], the Morquio A Clinical Assessment
Program (MorCAP) (including 325 patients with MPS IVA) [11], the MPS VI Survey (including 121 patients with MPS VI) [13] and the Dutch MPS
Survey (including 55 patients with MPS I, II, III, IV, and VI) [15]
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Table 1 PROs used in patients with MPS
Name questionnaire Acronym Age range (yrs) Assessment of Completed
bya
Reference
Symptom PROs
Pain Visual Analog Scalesb VAS ≥8 Pain intensity Patient
Adolescent Pediatric Pain Tool APPT 8–17 Pain location, description and intensity Patient [60, 61]
Brief Pain Inventory Short Form BPI-SF Adults Severity of pain, impact of pain on daily
function, location of pain, use of pain
medications, amount of pain relief
Patient [30, 62]
Six-face Faces Pain Scale-Revised FPS-R ≥8 Pain intensity Patient [15]
Non-communicating Children’s
pain Checklist-Revised
NCCPC-R 3–18c Pain-associated behavior Observer [15, 63]
Achenbach System of Empirically
Based Assessment Adult Self
Report
ASEBA ASR 18–59 Social-adaptive and psychological symptoms Patient [30]
Achenbach System of Empirically
Based Assessment Older Adult
Self Report
ASEBA OASR ≥60 Social-adaptive and psychological symptoms Patient [30]
Yatabe-Guilford Personality testd Y-G test NA personality and psychiatric aspects Patient [31]
Tree-drawing test (Baum test) TDT NA personality and psychiatric aspects Patient [31]
General Health Questionnaire 60 GHQ-60 Adolescents and
adults
Mental health Patient [31]
State-Trait Anxiety Inventory STAI Adolescents and
adults
Anxiety Patient [31]
Functioning PROs
Health Assessment
Questionnaire
HAQ >18 Functional capacity and independence in
activities of daily living, pain, overall well-being
Patient [13, 64]
Childhood Health Assessment
Questionnaire
CHAQ ≤18 Patient [13, 65]
Mucopolysaccharidosis Health
Assessment Questionnaire
MPS HAQ Children and
adults
Self-care, mobility skills, extent of caregiver
assistance in performing activities
Patient [32]
Hunter Syndrome-Functional
Outcomes for Clinical
Understanding Scale
HS-FOCUS Children (>12) and
adults
Impact of MPS II on function Patient [27]
Modified version of the
Functional Independence
Measuree
FIM Children and
adults
Physical and cognitive disability Observer [31, 34]
Pediatric Evaluation of Disability
inventory
PEDI 0.5–7.5 Capability and performance in self-care,
mobility and social function
Patient or
parentf
[66, 67]
Vineland Adaptive Behavior
Scales
VABS Children and
adults
Adaptive behavior Parent/
caregiver
[36, 37,
39, 40]
Behavior Assessment System for
Children
BASC Children Emotional adjustment and adaptive behavior Patient
and/or
parent
[37]
Scales of Independent Behavior-
Revised
SIB-R Infancy-80+ Adaptive behavior Patient [68]
Health-related quality of life
EuroQol 5D EQ-5D Versions for
children (≥8) and
adults (≥16)
Physical and mental health Patient [28, 69]
Short form-36 SF-36 ≥16 Physical and mental health Patient [15, 30,
70]
Health Utilities Index HUI ≥5 Impact of disease and therapy Patient or
parent
[27]
Pediatric Quality of Life
inventory
PedsQL Children physical, emotional, social, and school
functioning
Patient or
parent
[15, 43,
71]
Hendriksz et al. Orphanet Journal of Rare Diseases  (2016) 11:119 Page 4 of 15
Disease impact on PROs in MPS
Impact of MPS on self-reported symptoms: pain, fatigue
and psychological health
Pain has been assessed as an exploratory endpoint in
several clinical trials evaluating ERT, mostly using the
(Childhood) Health Assessment Questionnaire ((C)HAQ)
Pain Scale or a modified version [23–26]. Baseline pain
measurements from these trials recorded before patients
were treated with ERT, and data from a number of other
studies using (C)HAQ (Tables 2 and 3), indicate that MPS
patients can experience considerable pain [23]. A score of
0.93 on a scale from 0 (no pain) to 3 (severe pain) has
been reported for untreated patients with MPS I (N = 30)
[23]. Mean Pain Scale scores reported for patients with
MPS VI in the phase II study and the MPS VI Survey
Study varied between 30 and 40 on a scale from 0 to 100,
corresponding with mild to moderate pain, while scores
were somewhat higher in older patients (>18 years)
[13, 25]. A score of 28 has been reported for patients
with attenuated MPS II [27].
Several studies have evaluated pain in MPS in more
detail using other questionnaires [15, 28, 29]. In the
Dutch National MPS Survey of 55 patients with differ-
ent types of MPS, joint pain was evaluated with the
Non-communicating Children’s Pain Checklist-Revised
(NCCPC-R), the Six-face Faces Pain Scale-Revised (FPS-R)
and an MPS-specific questionnaire. Overall, 69 % of pa-
tients reported pain, mainly hip and back pain (27.8 and
25.9 %, respectively), with a pain score above the critical
cut-off value for significant pain in 40 % of cases [15].
Somewhat surprisingly, pain was most frequently reported
for patients with cognitive impairment, particularly for
MPS III, while patients with MPS IV (which is not associ-
ated with cognitive impairment) appeared to experience
the most severe pain [15]. The unexpected high preva-
lence of pain in cognitively impaired patients suggests that
pain may be underestimated in this group, but may also
reflect difficulties with parents distinguishing between
MPS- and pain-related behavior (as assessed in the
NCCPC-R) in these patients.
The finding from the Dutch survey that pain was most
severe in MPS IV patients is not unexpected given the
severe skeletal and joint abnormalities in these individ-
uals. Consistent with this finding, a phase II MPS IVA
study reported a pain intensity score of 4.6 on the
Adolescent Pediatric Pain Tool (APPT) at baseline, indi-
cating medium pain [29]. In addition, an international
MPS IVA PRO survey reported joint pain in 74 % of adults
(N = 27) and 64 % of children (N = 36), as documented
using the Brief Pain Inventory Short Form (BPI-SF) and
APPT [28]. In both studies, pain was described most
often in the lower extremities [28, 29]. The PRO survey
also demonstrated an association between pain and
mobility as measured by wheelchair use. Adult patients
who sometimes used a wheelchair tended to report
more severe and widespread pain than those always
using a wheelchair, while pain interference with daily
activities was highest in the latter group [28]. This sug-
gests adult MPS IVA patients may tolerate considerable
pain if mobility and wheelchair independence are
retained.
Our literature search revealed only a single study
assessing fatigue. The aforementioned MPS IVA PRO
study, assessed fatigue/low stamina by querying patients
Table 1 PROs used in patients with MPS (Continued)
TNO-AZL Preschool children
Quality of Life
TAPQOL 0.5–5 Physical, social, cognitive, and emotional
functioning
Parent [72]
TNO-AZL Children Quality of Life TACQOL 6–15 Health status and children’s subjective
emotional appraisal of their health
Patient or
parent
[73]
Childhood Health Questionnaire CHQ 5–18 functional capacity and independence in
activities of daily life
Patient and
parent
[27, 37,
39]
Impact on family/caregivers
Pediatric Quality of Life
inventory Family Impact Module
PedsQL Family
Impact
Module
Children Parent’s problems in physical, emotional, social,
and cognitive functioning, communication, worry,
and problems specific to the family’s daily
activities and family relationships
Parent [74]
Zarit Burden Interview ZBI Adult patients Burden of caring on relationship, emotional
well-being, social and family life, finances,
control over one’s life
Parent/
caregiver
[8]
aIn MPS studies
bPain VAS scores that have been used in MPS patients are included in the HAQ, CHAQ, EQ-5D, APPT
cPatients who are unable to speak because of intellectual impairments or disabilities
dJapanese version of the Guilford test
eAdapted for patients with MPS
fNormally completed by parent or observer
NA not available
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on the number of evenings per week that they reported
feeling extremely tired. Using this definition, 63 % of
adults and 69 % of children reported feeling fatigued, a
high prevalence warranting further investigation. Possible
contributions from pulmonary or cardiac causes would be
difficult to distinguish in many patients.
To date, two studies have evaluated the psychological
health of patients with MPS [30, 31]. A study in ten
MPS II patients showed that many had difficulties estab-
lishing relationships and that patients and their parents
had increased levels of anxiety [31]. A correlation was
found between psychological status and ADL, suggesting
that reduced ADL negatively affects psychological status
[31]. Another study of 20 MPS IVA patients showed psy-
chological symptoms (at least one or more ASEBA
[Achenbach System of Empirically Based Assessment,
which assesses social-adaptive function deficits and psycho-
logical symptoms] problem Scales within the symptomatic
range) in 11 individuals [30]. Interestingly, these patients
had higher pain severity scores and pain interference scores
on the BPI, suggesting that pain and psychological issues,
including depression, may be interdependent.
Table 2 Clinical studies assessing PROs in patients with MPS, excluding ERT trials
Reference MPS type N Age (yrs) PRO instrument
[40] MPS IH 41 NAa VABS
[39] MPS IH 47 Mean 10.5 VABS II
CHQ
[34] MPS II 27 5–41 FIM
[31] MPS II 10 Mean 23.2 FIM
Personality tests: Y-G test, Tree-drawing test
Psychological tests: GHQ-60, STAI
[38] MPS II 50 Mean 6.0 Different standardized tests for cognitive, adaptive,
language, and motor functions
[35] MPS II 29 Mean 11.5 MPS HAQ
[27] MPS II 96 patients & caregivers Mean 14.2 CHAQ
HS-FOCUSb
CHQ
HUI3
[36, 43] MPS II 73 patients & parents Mean 12.5 PedsQL
Peds QL Family Impact Module
VABS II
[37] MPS II 15 10.8 VABS II
CHQ
BASC-2
[14] MPS IVA 326 1–73 (C)HAQ
[11] MPS IVA 325 Mean 14.5 MPS HAQ
[8, 28] MPS IVA 63 patients
56 caregivers
5–17 years (N = 36)
≥18 years (N = 27)
Patients: EQ-5D, APPT (<18 years)/BPI-SF (≥18 years),
fatigue question
Caregivers : caregiver questionnaire, ZBI
[30] MPS IVA 20 NA ASEBA ASR/ OASR
SF-36
BPI
[41] MPS VIA 24 10–17 (N = 10)
18–54 (N = 14)
EQ-5D
[13] MPS VI 121c 4–56 (C)HAQ
[15] MPS I, II, III, IV, VI 55 Median 11.3 MPS-specific questionnaire
NCCPC-Rd
FPS-Rd
Pain VASd
SF-36d
PedsQL
[42] MPS I, II, IVA, IVB, VI 81 ≥18 EQ-5D
amean age at transplant was 21.7 months; mean years of follow-up from transplant was 67.2 months
bHS-FOCUS completed by 53 patients aged ≥12 years
cDisability, Pain and Arthritis scores for 91, 90, and 81 patients ≤18 years, respectively and Disability and Pain scores for 29 and 28 patients >18 years, respectively
dNCCPC-R was completed by parents of patients <8 years or with intellectual disability (N = 35) and the FPS-R by patients 8–18 years with no intellectual disability
(N = 11); eight patients completed the Pain VAS, 16 patients over 18 years completed the SF-36; 35 participants (patients or parents) completed the PedsQL
NA not available
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Impact of MPS on patient functionality
ADL, as assessed by the MPS Health Assessment Question-
naire (MPS HAQ), have been measured as an exploratory
endpoint in some clinical trials [32, 33], as well as in a
number of studies in patients with MPS II, IV and VI
[11, 14, 34, 35] (Table 2). Overall difficulties with mo-
bility and self-care, which tend to increase with age,
have been reported. In patients with MPS II, cognitive
decline negatively affects ADL.
A study of 96 patients with attenuated MPS II (age
5.0–30.9 years) reported impairments in walking/stand-
ing and reach/grip domains of the Hunter Syndrome-
Functional Outcomes for Clinical Understanding Scale
(HS-FOCUS) and impairments in hygiene, reach and
dressing, and grooming domains of the CHAQ [27]. HS-
FOCUS function scores were lower in patients with bet-
ter endurance in the 6MWT (r = −0.6) and better joint
mobility (r = −0.3). Another smaller study (N = 29; age
2–29 years) suggested that difficulties with ADL (as
assessed using the MPS HAQ) in MPS II patients mainly
depend on the cognitive status and age of these patients
[35]. Younger patients with normal mental development
were generally independent with regard to self-care,
mobility and walking, but assistance with daily activities
increased with age [35]. Cognitively impaired MPS II
patients required moderate or complete caregiver assistance
in self-care within all categories [35]. Two studies used the
Functional Independence Measure (FIM) to assess ADL in
patients with MPS II [31, 34]. In patients with severe MPS
II, cognitive scores decreased rapidly, reaching a minimum
score at about 7 years of age, in contrast to motor scores,
which decreased more slowly. In slowly progressing MPS II
patients, total FIM scores increased with age, similar to in-
creases in FIM scores seen in healthy children [34]. In pa-
tients with MPS II, daily living skills have also been
assessed as part of adaptive behavior scales [36, 37]. In both
mild and severe forms of MPS II (N = 73), the Vineland-II
Adaptive Behavior Scales (VABS II) showed significantly re-
duced functioning in communication, daily living skills,
socialization, and motor skills as compared to normative
data [36], but scores were significantly lower (more severe)
in severe than in mild MPS II. A study including 15 pa-
tients with slowly progressing MPS II showed adaptive
skills within the average range on the VABS II, as well as
Table 3 Clinical studies assessing the impact of ERT on PROs in MPS patients
Reference MPS type Treatment Comparator N Mean age (years)a Study duration PRO instrument
[33] I
83 % Hurler-Scheie,
13 % Scheie
iv laronidase
(0.58 mg/kg/week)
Placebo 45 15.6 26 weeks (C)HAQ
[23] I iv laronidase
(0.58 mg/kg/week)
/ 45 15.7 3.5 year
(extension of [66]
(C)HAQ
[52] I iv laronidase
(0.58 mg/kg/week)
/ 5 12.0 6 year Modified MPS HAQ
[53] I
Scheie, Hurler- Scheie
iv laronidase
(0.58 mg/kg/week)
/ 7 16.3 52–208 weeks MPS HAQ
[55] II iv idursulfase
(0.5 mg/kg/week)
/ 94 14.5 2 years extension (C)HAQ
[32, 45] IVA iv elosulfase alfa
(2.0 mg/kg every other
week or weekly)
Placebo 176 15.3 and 13.1 24 weeks MPS HAQ
[29] IVA iv elosulfase alfa
(2.0 or 4.0 mg/kg/week)
/ 25 13.7 27 weeks APPT
[24] VI iv galsulfase
(1.0 or 2.0 mg/kg/week)
/ 5 11.0 48 weeks (C)HAQ
[25] VI iv galsulfase
(1.0 mg/kg/week)
/ 10 12.7 48 weeks (C)HAQ
[26] VI iv galsulfase
(1.0 mg/kg/week)
Placebo 39 13.7 24 weeks Joint pain and stiffness,
physical energy level
[56] VI iv galsulfase
(1.0 mg/kg/week)
/ 9 NA 2 years (C)HAQ
[5] VI iv galsulfase
(1.0 mg/kg/week)
/ 55 12.0 6.8 ± 2.2 years (C)HAQ
[44] VI iv galsulfase
(1.0 mg/kg/week)
/ 8 6.8 1.0–4.5 years TAPQOL/TACQOLb
aMean age at baseline from all patients or from ERT group
bThe TAPQOL was completed by the parents of four patients <6 years, TACQOL was completed by seven parents of patients ≥6 years
NA not available
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the Behavior Assessment System for Children (BASC)-2
Parent Rating Scale [37]. Daily living skills domain scores of
the VABS II decreased significantly with age across patients.
Children aged ≥12 years showed an increasing sense of in-
adequacy and anxiety as well as decreasing self-esteem over
time in the BASC-2. In a retrospective review of longi-
tudinal data from 50 patients with MPS II, two groups
of patients could be distinguished based on adaptive be-
havior data (obtained using the Scales of Independent Be-
havior, Revised [SIB-R] and the Pediatric Evaluation of
Disability Inventory [PEDI]): one group reaching a plateau
at around 48–60 months and then declining and one
group maintaining relatively normal adaptive abilities over
time [38]. In patients with MPS IH, the VABS has been
used to evaluate the impact of HSCT on adaptive skills
[39, 40]. These studies are discussed below under “Effects
of therapy on HRQoL in MPS”.
MPS IVA and MPS VI have also been shown to signifi-
cantly interfere with patients’ADL [14]. In the International
Morquio A registry of 326 MPS IVA patients, only 40–
60 % of patients were able to perform ADL independently
[14]. In the MorCAP study with 325 MPS IVA patients,
20–40 % reported self-care ADL tasks (including the ability
to wash or brush hair, tie shoelaces and cut fingernails)
were affected by their disease (Fig. 3) [11]. In the Survey
Study of 121 MPS VI patients, the (C)HAQ disability index
indicated a mild level of disability in patients aged >18 years
(mean 1.0) and moderate disability in those aged ≤18 years
(mean 2.0) [13].
Impact of MPS on health-related quality of life (HRQoL)
Several studies report significant disease impact on HRQoL
in patients with MPS disorders (Table 2). Overall, the
greatest deviations from a healthy population were seen
in domains of pain/discomfort and mobility. Problems
with self-care or usual activities were also critical factors
affecting HRQoL. In addition, wheelchair use, unemploy-
ment, poor endurance, and poor pulmonary function were
also associated with worse HRQoL [28, 41]. Despite the
deviation in pain domains, no differences in HRQoL could
be found between patients with or without pain [15, 28].
Although pain has been identified as a significant issue for
patients with MPS, other symptoms such as mobility ap-
pear to have greater impact on HRQoL.
Two studies used the generic Short Form-36 (SF-36)
to assess HRQoL in patients with MPS (Table 2). In 16
adults from the Dutch national MPS survey, including
patients with MPS I, II, III, IV and VI, deviations from
average were predominantly seen in the physical compo-
nent score (29–30 vs. 50 in a reference population) [15].
The largest deviation was observed in the bodily pain
domain (37–41 vs. 81), possibly due to bone pain re-
ported in 68 % of patients. The Pediatric Quality of Life
(PedsQL) was used in this study to assess HRQoL in
patients <18 years, showing the largest deviations com-
pared with healthy individuals in the PedsQL physical
score (53–57 vs. 79–85 in a reference population). A
study including 20 patients with MPS IV recently showed
scores below the US mean in physical, but not mental,
health on the SF-36 [30]. Although several patients had
psychological symptoms on the ASEBA Adult Self-Report
(ASR), these did not seem to affect HRQoL outcomes.
Two studies used the generic Euroqol-5 dimensions
(EQ-5D) questionnaire, assessing mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression in pa-
tients with MPS. Lavery et al. examined 81 adult patients
from the UK and USA with various types of MPS and a
mean utility value of 64.1 (with 100 indicating best health)
[42]. HRQoL in these patients was mainly affected by mo-
bility impairment and pain/discomfort, and to a lesser de-
gree by problems with self-care or performing usual
activities [42]. In the international PRO survey using the
EQ-5D, Hendriksz et al. [28] reported impairment in mo-
bility, self-care, usual activities, pain/discomfort, and anx-
iety/depression for both adults (N = 27) and children (N =
36) with MPS IVA (Fig. 4). Results from this study
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indicated that HRQoL diminished with increasing wheel-
chair use. Adult patients who used a wheelchair sometimes
(when needed) had a mean utility value of 0.582, a score
comparable to that for patients with chronic ischemic heart
disease or non-insulin dependent diabetes mellitus (Table 4).
The utility value of adults using a wheelchair all the time
(0.057) was only slightly better than that of bed ridden or
completely immobile multiple sclerosis patients (Table 4).
EQ-5D utility values were also considerably lower in un-
employed (0.275) than in employed (0.640) MPS patients
[28]. A study in a subset of German MPS IVA patients
(N = 24) from the international PRO survey showed
strong correlations of EQ-5D utility values with endur-
ance in the 6-min walk test and 3-min stair climb test
(R = 0.884 and R = 0.852, respectively) and with pulmonary
function (forced vital capacity: R = 0.815; maximum volun-
tary ventilation: R = 0.825), suggesting that these measures
might be used as surrogate measures for HRQoL in pa-
tients with MPS IVA [41].
Several MPS studies have used generic instruments to
measure HRQoL in children. The Dutch national MPS
survey of patients with MPS I, II, III, IV and VI [15] used
the PedsQL to assess HRQoL in patients <18 years, with
the largest deviations compared to healthy individuals
seen in the PedsQL physical score (53–57 vs. 79–85 in a
reference population). The PedsQL was also used in a
study of 73 patients with MPS II and their parents,
showing reduced scores in all domains (physical, emo-
tional, social, and school functioning) versus healthy
individuals and patients with several other chronic ill-
nesses (cancer, maple syrup urine disease, galactosemia)
[43]. In slowly progressing MPS II patients (N = 96),
Raluy-Callado et al. [27] demonstrated significant dis-
tress and dysfunction in global health, physical function-
ing and role/social-limitations-physical and bodily pain,
as measured by the generic Childhood Health Question-
naire (CHQ) (N = 96). Low scores were reported in the
self-esteem and family cohesion domains, suggesting
that MPS II has a severe psychological impact on pa-
tients and their parental caregivers. It is unclear how
these domains were affected by cognitive function. A clear
correlation between joint ROM and better physical func-
tioning scores of the CHQ (r = 0.5) was observed. A
smaller study in 15 slowly progressing MPS II patients
showed a CHQ psychosocial summary score within the
normal range. The physical summary score was 1.5
standard deviations below the normative average for
the whole group, >2 standard deviations below average
in children ≥12 years (N = 10), and tended to worsen
with age [37].
Finally, Brands et al. [44] used the TNO-AZL Child
Quality of Life (TACQOL) and TNO-AZL Preschool
Children’s Quality of Life (TAPQOL) questionnaires to
evaluate the impact of ERT on HRQoL in children with
MPS VI aged 6–15 years (N = 7) and aged 6 months to
6 years (N = 4), respectively (Table 3). Baseline data
reflected the greatest deviations from healthy peers in
lung problems, social functioning, motor functioning
and positive mood domains of the TAPQOL and in body
and motor domains of the TACQOL [44].
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Table 4 Comparison of HRQoL according to the EQ-5D utility
value in MPS IVA (Morquio A) patients with different levels of
mobility impairment and other serious chronic diseases
Disease HRQoL mean utilitya
MPS IVA: adults, no wheelchair [28] 0.846
MPS IVA: adults, sometimes wheelchair [28] 0.582
MPS IVA: adults, always wheelchair [28] 0.057
Multiple sclerosis, walking-aid [75] 0.460
Multiple sclerosis, bedridden [75] −0.195
Moderate to severe rheumatoid arthritis [76] 0.489
Chronic ischaemic heart disease [77] 0.640
Non-insulin dependent diabetes mellitus [77] 0.670
aEQ-5D utility scores were calculated using a time tradeoff method [78]. This
generates scores ranging from −0.59 to 1, where 1 means full health and zero
stands for death. Negative scores could be emotively interpreted as a health
state “worse than death”. Tradeoff tariffs used differed depending on the
ethnic background of patients
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Impact of MPS on caregivers
Only a few studies, to date, have addressed the impact
on caregivers looking after individuals with MPS. In a
study including 73 caregivers of patients with MPS II
(both mild and severe forms), the PedsQL Family Impact
Module showed that the impact of the disease on the
family is similar to that for other pediatric outpatients
with chronic illnesses [36]. Domain scores for family
HRQoL, family functioning summary, total scale score,
physical functioning, social function, daily activities, and
family relationships negatively correlated with the sever-
ity of illness. In the international PRO survey in MPS
IVA patients [8], outcomes of the Zarit Burden Interview
(ZBI), the MPS HAQ, and a caregiver questionnaire re-
vealed that MPS IVA poses a large burden on caregivers,
affecting their physical and emotional health, family life,
social life and financial situation. Caregiver burden in-
creased with disease progression and mobility problems.
Wheelchair use by MPS IVA patients had a profound
negative impact on caregiver’s support (Fig. 5) [8]. Be-
cause wheelchair-bound patients require much more
caregiver support than those using a wheelchair occa-
sionally, the investigators concluded that even small
improvements in patient mobility might substantially
reduce the level of caregiver support and the burden
of caregiving.
Effects of therapy on HRQoL in MPS
Therapies for MPS
Two treatment options target the pathophysiology of
MPS: HSCT and ERT. HSCT is primarily used in MPS
conditions with a neurologic component since difficulties
exist in delivery of intravenous enzyme products across
the blood-brain barrier [9]. ERT is currently available to
treat MPS I, II, IVA and VI. Several randomized, placebo-
controlled phase II/III clinical studies have demonstrated
favorable effects of ERT on urinary GAG levels, endur-
ance, respiratory function, joint ROM, hepatomegaly,
growth/height, and cardiac function [25, 45–49].
HSCT
While HSCT has been considered the standard of care
for the severe form of MPS I (Hurler syndrome) for de-
cades [50], effects on patient reported HRQoL are not
well studied. A few studies in patients with MPS IH and
MPS II have been published.
A study of 41 MPS IH children transplanted at a mean
age of 21.7 months and followed for 2–21 years (mean
follow-up 67.2 months) showed declining adaptive be-
havior scores on the VABS over time, indicating develop-
ment of skills at a lower than average rate compared
with unaffected peers [40]. VABS scores were signifi-
cantly better in transplanted patients after the age of
2 years when compared to a cross-sectional non-
transplanted MPS IH group. Cognitive ability, not age,
at transplant correlated significantly with the ultimate
adaptive level. Another study of 47 MPS IH patients
transplanted between 6 and 44 months and evaluated
1–24 years post-HSCT showed no significant impact
of the type of transplant, number of transplants, age at
transplant, time since transplant, or total body irradiation
treatment on adaptive functioning on the VABS. [39].
However, individuals undergoing HSCT at an older age re-
ported poorer physical QoL on the CHQ. In addition, pa-
tients receiving unrelated bone marrow HSCT exhibited
poorer psychosocial QoL compared with those receiving
bone marrow HSCT from a relative.
Finally, a retrospective study in 13 HSCT-treated,
Japanese MPS II patients showed stable or improved
ADL (school status, movement and daily activities, con-
versation, and toileting) versus baseline in most patients
after a mean follow-up of 9.6 years [51].
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ERT
Several clinical trials evaluating ERT in patients with
MPS I, II, IVA and VI have included PRO measures as
exploratory efficacy endpoints using the (C)HAQ or MPS
HAQ (Table 3). It should be noted that these studies were
not powered to assess the true effect of ERT on PRO mea-
sures and results should be interpreted with caution.
MPS I
Studies in patients with MPS I describe improvements
in ADL, pain and HRQoL after long-term ERT [23, 52, 53].
The 3.5-year extension of the laronidase phase III study
(N = 45) showed a stable or improved (C)HAQ Disabil-
ity Index in 77 % of patients (57 % improved) [23]. The
mean decrease of 0.31 was considered clinically mean-
ingful based on data from patients with rheumatoid
arthritis [54]. In the 30 patients in this study with avail-
able pain data, the Pain Index decreased from 0.93 at
baseline to 0.56 after long-term treatment. A smaller
study of 7 patients with attenuated MPS I (Scheie or
Hurler-Scheie) showed significant improvements in
ADL (eating/drinking, dressing, tooth brushing, toilet-
ing, and walking) as documented by the MPS HAQ
after 52–208 weeks of ERT [53]. The impact of ERT on
HRQoL in patients with MPS I has been assessed in a
6-year re-evaluation of patients enrolled in the original
laronidase phase I/II trial using an MPS-specific QoL
questionnaire containing 100 questions. The largest ef-
fects of treatment were reported for energy, endurance,
independence (personal hygiene, dressing, transfers),
sleep quality, participation in daily activities, and self-
esteem [52].
MPS II
One long-term open-label study has investigated the
effect of ERT on PRO measures in patients with MPS
II. This study demonstrated statistically significant im-
provements from baseline in the CHAQ Disability
Index in 48 patients aged ≥12 years as soon as 20 months
after ERT initiation [55]. Disability was also evaluated by a
parent-assessed Disability Index completed by 81 parents,
showing significant improvements 8 months after onset
of ERT.
MPS IVA
Studies in patients with MPS IVA have shown improve-
ments in ADL and pain within a relatively short time
after ERT initiation [29, 32, 45]. The MPS HAQ was
used to evaluate the effect of ERT on ADL in 176 pa-
tients with MPS IVA in a phase III study. After 24 weeks,
small to modest improvements in caregiver assistance
and mobility domains were observed for ERT compared
to placebo, though with wide confidence intervals [32, 45].
Interim results of an ongoing randomized, double-blind
study in 25 MPS IVA patients with relatively good endur-
ance showed clear (numerical) improvements in pain, as
assessed using the APPT, after 24 weeks of ERT [29].
MPS VI
Studies in patients with MPS VI have shown improve-
ments or no change in ADL, pain and HRQoL in patients
receiving ERT [5, 24–26, 44, 56]. The (C)HAQ, or a
modified version, was used in all clinical trials evaluating
the efficacy of ERT in MPS VI, showing improvements in
pain and arthritis or joint stiffness and improvements in
ADL (e.g. picking up coins, tying shoelaces, pulling
shirt overhead) as measured by investigator observation
in the phase I/II and phase II studies [24, 25]. In a
small Taiwanese open-label study, nine patients showed
an improvement in the (C)HAQ Disability Index with
ERT [56]. However, these results could not be confirmed
in the phase III study, which reported no changes in any
of the tertiary efficacy measures [26]. Similarly, a 10-year
Resurvey of the MPS VI Survey Study reported no change
in the HAQ disability, pain and arthritis scores from base-
line in patients receiving ERT for a mean period of
6.8 years despite the fact that most of the participants had
rapidly progressing phenotypes [5]. A Dutch study of 11
patients with MPS VI showed improvements with ERT in
lung problems, sleeping, liveliness, positive mood, social
functioning, and communication domains of the TAPQOL
in younger patients and in body and motor domains of the
TACQOL in older patients [44].
Discussion and conclusions
In recent years, more patient-centric studies have
attempted to measure the burden of illness as it relates
to individuals with MPS disorders. The varied clinical
manifestations of MPS disorders, from skeletal, pulmonary
and cardiac impairment to psychological, fatigue and pain
management issues make this group of diseases unique
and challenging from both the clinicians’ and patients’ per-
spective. The use of formal PRO tools to measure ADL
and HRQoL has given researchers much insight into what
patients living with a progressive, debilitating disease like
MPS go through on a daily basis. While recent studies
have specifically focused on PROs as clinically meaningful
measures for functioning and life, PROs were previously
mainly used as exploratory endpoints in clinical trials. Our
review of the current literature demonstrates that HRQoL
is strongly negatively affected in both MPS patients and
their caregivers, with mobility, pain and psychological is-
sues being significant problem areas. Two approved treat-
ments for MPS are currently available, HSCT and ERT.
The effects of HSCT on patient reported HRQoL has not
been adequately addressed to date and future research is
warranted. Multiple studies in patients with MPS I, IVA
and VI receiving ERT report improvements in ADL, pain
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and HRQoL. Clinicians, industry, regulatory agencies and
payers increasingly recognize the importance of PROs in
the evaluation of new therapies. PROs should continue to
be utilized in future ERT studies as primary or secondary
endpoints to capture relevant data on HRQoL and there is
both the opportunity and the need to validate and expand
the routine use of customized MPS-specific HRQoL tools.
While PRO measures often provide important infor-
mation about the burden of illness in patients with MPS,
they may be limited in their use, particularly in children
or adolescents. HRQoL is a multi-dimensional concept
that includes subjective evaluations, which can be chal-
lenging to measure due to heterogeneity in number and
content of domain items included in questionnaires, dis-
crepancies between patient and parent ratings, and lack
of information regarding test–retest reliability, structural
validity, or sensitivity to change [57, 58]. It is also im-
portant to keep in mind that while functional status may
be related to HRQoL, functionality may not always be
indicative of a patient’s subjective perception of his or
her life [57, 59]. For example, children who have never
experienced a healthy state and who have adapted to this
condition may have a good HRQoL despite their func-
tional limitations [57]. In addition, the impact of physical,
social, and cognitive factors on HRQoL can change with
age [59]. Social roles and independence may be more im-
portant for HRQoL in adolescents than for children [59].
Therefore, the terms HRQOL, health status, and function-
ing should not be used interchangeably, and different
types of items and response formats should be used for
different ages or developmental levels. Although several
generic PRO tools used in MPS studies are validated and
allow comparisons across diseases, disease-specific PRO
measures may be more suitable as endpoints in clinical tri-
als as they are more likely to detect clinically meaningful
changes [58, 59].
The results of PRO assessments should always be seen
in the socio-cultural and economic context in which
they exist and should take into account the patient’s per-
sonality, cognitive ability, and community support net-
work. In addition, ADL measures need to become broader
in scope to capture technical advances of the modern
world that increasingly impact, both positively and nega-
tively, the lives of patients. Finally, it is important to keep
in mind that a patient’s medical status is only a part of his
or her personality. It is hoped that QoL assessments do
not provoke alienation from a patient’s own personality
and curtail his or her ability to flourish. To address these
challenges, health professionals and patients should de-
velop partnerships to exchange academic and life experi-
ences. As the MPS disorders are rare diseases and patients
are spread over many centers, it will be important to de-
velop a unified approach for monitoring PROs in these
patients.
In closing, the impact of MPS on subjective symptoms,
functionality, and HRQoL is a critical area of investigation
in the field of lysosomal storage disorders. Development
of valid and reliable assessment tools and implementation
of routine evaluations could lead to early identification
of areas of difficulty and subsequent intervention, min-
imizing the negative impact of MPS-related problems.
Managing the negative effects of MPS through early
identification and treatment will prove vital for both
patients and caregivers. Ultimately, focusing on the pri-
mary medical disease alone is not enough when treat-
ing patients with a chronic illness. Considering the
entire person’s biology, psychology, and social circum-
stances will ultimately lead to improved patient out-
comes and a better understanding of the unique
challenges they face.
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